Abbott Laboratories (NYSE:ABT – Get Free Report) has been assigned an average rating of “Moderate Buy” from the twenty-six research firms that are covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation, nineteen have issued a buy recommendation and three have issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $118.6087.
ABT has been the topic of several research reports. Evercore lowered their price objective on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Daiwa Securities Group downgraded shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price for the company. in a research note on Wednesday, April 22nd. Argus lowered their price target on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, April 21st. Weiss Ratings raised Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, July 7th. Finally, Benchmark decreased their price objective on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th.
Get Our Latest Stock Report on ABT
Insiders Place Their Bets
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in ABT. Oakworth Capital Inc. raised its holdings in Abbott Laboratories by 49.5% during the second quarter. Oakworth Capital Inc. now owns 11,832 shares of the healthcare product maker’s stock worth $1,076,000 after purchasing an additional 3,916 shares in the last quarter. Albion Financial Group UT boosted its holdings in Abbott Laboratories by 1.8% in the 2nd quarter. Albion Financial Group UT now owns 15,256 shares of the healthcare product maker’s stock valued at $1,384,000 after purchasing an additional 264 shares in the last quarter. Atlatl Advisers LLC acquired a new position in Abbott Laboratories during the 2nd quarter worth approximately $78,000. Confluence Wealth Services Inc. raised its stake in shares of Abbott Laboratories by 25.5% during the 2nd quarter. Confluence Wealth Services Inc. now owns 44,422 shares of the healthcare product maker’s stock worth $4,031,000 after buying an additional 9,031 shares in the last quarter. Finally, Exchange Traded Concepts LLC lifted its holdings in shares of Abbott Laboratories by 31.7% in the 2nd quarter. Exchange Traded Concepts LLC now owns 75,528 shares of the healthcare product maker’s stock valued at $6,853,000 after buying an additional 18,196 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.
Abbott Laboratories Trading Up 1.0%
ABT opened at $100.69 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The business’s 50 day moving average is $90.92 and its two-hundred day moving average is $101.48. The firm has a market cap of $175.38 billion, a price-to-earnings ratio of 32.59, a price-to-earnings-growth ratio of 1.93 and a beta of 0.61.
Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. The business had revenue of $12.51 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The company’s revenue was up 13.0% compared to the same quarter last year. During the same period in the prior year, the company earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts predict that Abbott Laboratories will post 5.51 EPS for the current year.
Abbott Laboratories Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.
Abbott Laboratories Company Profile
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
Read More
- Five stocks we like better than Abbott Laboratories
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
